17-Mar-2025
Study: suppressing key protein may unlock immunotherapy for Glioblastoma
University of Miami Miller School of MedicinePeer-Reviewed Publication
Glioblastoma has remained one of the toughest cancers to treat, but new research suggests that suppressing a protein (ZNF638) triggers an antiviral immune response, making immune checkpoint inhibitors more effective. The discovery not only offers a potential new treatment strategy but also identifies ZNF638 as a biomarker that could help personalize immunotherapy.
- Journal
- Journal of Clinical Investigation
- Funder
- NIH/National Cancer Institute, Elsa Pardee Foundation, NIH NCI K12 Calabresi Award, UM American Can¬cer Society Intramural Funding, Florida Center for Brain Tumor Research, NREF, NIH/National Cancer Institute, NIH/National Cancer Institute, NIH/National Cancer Institute, Dwoskin Family Fund, Vivex Foundational Grant